Moreover, it was later demonstrated that MM cells express significantly higher levels of GPRC5D mRNA and protein as compared to normal plasma cells, and, importantly, MM patients’ plasma cells continue to express GPRC5D after therapy with immunomodulatory drugs, proteasome inhibitors, or CD38-targeting antibodies [175]. Here, CD38 is linked to Miyoshi myopathy.